Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand

Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.

DVAXPositive Net Change MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.

AZNPositive Net Change MRKPositive Net Change AMGNNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

SNYPositive Net Change GSKPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change